/** blogpostTitle: Hikal Q4 FY26: Margin recovery, but FY26 weighed down by exceptional items */

Hikal Q4 FY26: Margin recovery, but FY26 weighed down by exceptional items

Hikal ended Q4 FY26 on a stronger operating note even as the full year FY26 remained weak on reported profitability. For Q4 FY26, consolidated revenue came in at 519 crore and EBITDA at 105 crore, translating into a 20.3% EBITDA margin. Reported PAT for the quarter was 14 crore, while results included an impairment charge at Panoli.

For FY26, consolidated revenue was 1,713 crore versus 1,860 crore in FY25. EBITDA declined to 220 crore and the EBITDA margin fell to 12.9% from 17.7% in FY25. Reported net profit for FY26 was negative 49 crore, driven by exceptional items of 85 crore. These comprised the effect of the new labour code (38 crore) and impairment of a manufacturing asset at Panoli (47 crore).

Q4 showed operating normalization

Management framed Q4 and the recent quarters as a transition from remediation and normalization towards sustainable growth. The improvement in Q4 margins was supported by better operating leverage and a recovery in the Crop Protection business. Segment mix also shifted in Q4, with Crop Protection contributing 44% of consolidated revenue versus 32% in Q3.

Pharmaceuticals remained the larger segment but saw lower revenue in Q4 at 292 crore versus 337 crore in Q3. Despite this, management indicated sequential improvement in margins due to product mix. The company also highlighted that H2 FY26 pharma revenue grew 60% to 629 crore over H1 FY26, as demand trends improved and customer ordering patterns normalized.

Financial snapshot

Segment performance: Crop Protection led the quarter

In Q4 FY26, Crop Protection revenue rose to 228 crore from 157 crore in Q3 and 201 crore in Q4 FY25. The segment delivered EBIT of 39 crore in Q4, compared with 5 crore in Q3. Management attributed the improvement to higher volumes and gradual normalization after several years of industry inventory correction.

For FY26, Crop Protection revenue was flat at 692 crore, but EBIT declined to 51 crore from 79 crore in FY25, reflecting a tougher pricing cycle and competitive intensity. Management remained cautious on pricing, citing structural overcapacity and Chinese competition, even as it expressed confidence that the worst phase of the volume cycle is behind.

Pharmaceuticals delivered FY26 revenue of 1,021 crore versus 1,168 crore in FY25. Segment EBIT declined to 33 crore in FY26 from 137 crore in FY25. On the earnings call, management linked the slower performance to the US FDA warning letter at the Bengaluru site and the decision to slow down certain production and release processes to strengthen compliance.

Revenue mix trends

Compliance and capability investments are central to the FY27 narrative

The key swing factor for the pharma business remains the path to normalization after the US FDA warning letter at the Bengaluru site. Management said it has not lost customers but acknowledged that shipments and product releases were slowed in the last quarter due to added checks and system pressure testing. It also stated that the order book is intact, though some quarterly business was lost and expected to return over subsequent quarters.

Management indicated that remediation-related CAPAs are nearing completion. It also stated that it is engaging continuously with the FDA, expects to complete milestones in the next few months, and anticipates an inspection towards the end of the year. In response to an investor question, management said such matters typically take 18 to 24 months to resolve.

Alongside remediation, Hikal is positioning its next growth phase around differentiated chemistry capabilities. Investments highlighted as operational include the high potency laboratory at the Pune R and D facility and a pilot plant at Panoli. The company also stated it is increasing DMF filings to 5 to 6 annually compared with 2 to 3 historically.

In parallel, management discussed next generation technologies such as HPAPIs and ADC related chemistries. It clarified that the company is targeting payload and linker synthesis rather than biologics. Management described this as a long-term opportunity that could take 3 to 5 years to scale meaningfully, with a planned HPAPI manufacturing facility in Pune targeted over FY28.

Costs, cash flows and balance sheet discipline

A near-term variable highlighted on the call was the rise in solvent prices since March. Management said availability is not a concern, but prices remain at elevated levels. It noted that CDMO contracts generally have pass-through mechanisms, though with a lag of about a quarter, and discussions with customers were in progress.

Cash flows remained a relative positive in FY26. Net cash inflow from operating activities was 302 crore in FY26 versus 280 crore in FY25, despite the weak reported profit line. The consolidated balance sheet showed total borrowings (current plus non-current) of 681 crore at March 2026 versus 762 crore at March 2025.

What to watch

Hikal did not provide explicit FY27 guidance on the call, citing uncertainty related to war-driven volatility in raw materials and logistics. However, management stated that FY27 should see growth and it would be in a better position to provide guidance after Q1.

The near-term checklist for investors remains clear. First is progress towards resolving the US FDA overhang and the return of normal shipment cadence. Second is whether the operationalized investments in high potency and integrated development translate into higher value CDMO wins. Third is the sustainability of the Crop Protection volume recovery in an environment where pricing remains competitive.

FY26 was shaped by exceptional items and remediation-linked slowdown. Q4 offered a snapshot of what improved utilization and product mix can do to margins. The market will now look for consistency through FY27, especially on compliance closure and conversion of the CDMO pipeline into commercial revenues.